Compare, Analyse VENUS REMEDIES with ACTAVIS INC. - US - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ACTAVIS (US) - Comparison Results

ACTAVIS (US)
   Change

Actavis, Inc. is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products. It develops, manufactures and market generic, branded generic, legacy brands and Over... More

DO YOU LIKE THESE REPORTS? TELL US!

Financials

 VENUS REMEDIES   ACTAVIS
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
ACTAVIS
Dec-18
VENUS REMEDIES/
ACTAVIS
5-Yr Chart
Click to enlarge
High Rs12614,478-   
Low Rs619,712-   
Sales per share (Unadj.) Rs301.83,551.4-  
Earnings per share (Unadj.) Rs-24.9-1,143.9-  
Cash flow per share (Unadj.) Rs2.5374.2-  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs293.314,647.7-  
Shares outstanding (eoy) m12.34332.60-   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.4 9.1%   
Avg P/E ratio x-3.8-10.6 35.6%  
P/CF ratio (eoy) x36.732.3 113.7%  
Price / Book Value ratio x0.30.8 38.6%  
Dividend payout %00-   
Avg Mkt Cap Rs m1,1544,022,682 0.0%   
No. of employees `0000.916.9 5.5%   
Total wages/salary Rs m3930-   
Avg. sales/employee Rs Th4,026.169,892.5 5.8%   
Avg. wages/employee Rs Th425.00-   
Avg. net profit/employee Rs Th-331.8-22,512.4 1.5%   
INCOME DATA
Net Sales Rs m3,7241,181,183 0.3%  
Other income Rs m2322,588 0.1%   
Total revenues Rs m3,7471,203,771 0.3%   
Gross profit Rs m39530,953 1.3%  
Depreciation Rs m338504,930 0.1%   
Interest Rs m35468,161 0.5%   
Profit before tax Rs m-275-519,550 0.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0132,506 0.0%   
Tax Rs m32-6,584 -0.5%   
Profit after tax Rs m-307-380,460 0.1%  
Gross profit margin %10.62.6 404.5%  
Effective tax rate %-11.51.3 -905.7%   
Net profit margin %-8.2-32.2 25.6%  
BALANCE SHEET DATA
Current assets Rs m2,638484,460 0.5%   
Current liabilities Rs m2,305428,569 0.5%   
Net working cap to sales %8.94.7 189.0%  
Current ratio x1.11.1 101.2%  
Inventory Days Days13520 691.5%  
Debtors Days Days4666 69.9%  
Net fixed assets Rs m4,871133,703 3.6%   
Share capital Rs m1230-   
"Free" reserves Rs m3,4960-   
Net worth Rs m3,6194,871,829 0.1%   
Long term debt Rs m1,3741,715,548 0.1%   
Total assets Rs m7,5097,615,778 0.1%  
Interest coverage x0.2-6.6 -3.4%   
Debt to equity ratio x0.40.4 107.8%  
Sales to assets ratio x0.50.2 319.8%   
Return on assets %0.6-4.1 -15.4%  
Return on equity %-8.5-7.8 108.6%  
Return on capital %1.6-4.8 -32.7%  
Exports to sales %00-   
Imports to sales %13.90-   
Net fx Rs m-5170-   
CASH FLOW
From Operations Rs m514421,992 0.1%  
From Investments Rs m-123231,830 -0.1%  
From Financial Activity Rs m-387-724,265 0.1%  
Net Cashflow Rs m4-70,091 -0.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster
The reporting currency for ACTAVIS (US) is United States Dollars. All data has been converted at 74.82 Rs / USD

Compare VENUS REMEDIES With: ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  

Compare VENUS REMEDIES With: WYETH  DR. REDDYS LAB  PIRAMAL ENTERPRISES  SUVEN LIFE SCIENCES  ALEMBIC  



Today's Market

Sensex Ends Flat; Wipro & Hindalco Industries Among Top Nifty Gainers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended on a flat note.

Related Views On News

VENUS REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 11.1% (Quarterly Result Update)

Jun 12, 2019 | Updated on Jun 12, 2019

For the quarter ended March 2019, VENUS REMEDIES has posted a net profit of Rs 104 m (down 11.1% YoY). Sales on the other hand came in at Rs 864 m (down 7.3% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games? (The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

4 Stocks to Make Your Portfolio Immune to the Second Covid Wave (Profit Hunter)

Apr 6, 2021

Rather than predicting the market, successful investing is more about preparing well and placing your bets accordingly.

A Stock with 700% Return Potential Comes with Additional Payoffs (Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

Why Did the Market Crash on Monday? (Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Unique Sector for Short-Term Profits (Fast Profits Daily)

Apr 12, 2021

This ignored sector could deliver big short-term profits.

More
-->

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

OUR TOP 5 IDEAS

Free Report: Multibagger Stock Ideas 2021
Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
Free Report: The Secret to Increasing Your Trading Profits Daily!
No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.

VENUS REMEDIES SHARE PRICE


Apr 16, 2021 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

FEATURED VIDEOS

Market Crash: Picture Abhi Baaki Hai?

It's a Great Time to Buy Gold

The Dilemma of Investing in Bharti Airtel

Nifty: Bear Trap?

More Featured Videos

MARKET STATS